Summary
88 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 116 USD is left as net profit.
- Revenue grew by 35% a year over the last 3 years.
- It earns 70 USD a year on every 100 USD of invested capital.
- It holds more cash than debt: $60.8M against $40.0M.
What to watch
- Its last loss-making year was 3 years ago.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 2.7 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 22% a year over 5 years. Over the last 3 years it grew by 35% a year.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 8.6 USD
- Research and development 16 USD
- Sales and administration 44 USD
- Taxes and other -85 USD
- Net profit 116 USD
Net profit, industry median (Biotechnology) -7.3 USD
Out of every 100 USD of revenue, 116 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 8
- Hold 7
- Sell 0
Today's price within the analysts' price targets
The average target of $67 is 43% above today's price. 53% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Product 79%
- Contract revenues from collaborations 21%
- Government Contract 0.1%
By region
The company reports no revenue by region.
Product brings in 79% of revenue.
Segments in detail